FTC出手，诺和诺德出局：辉瑞100亿美元收购Metsera后股价双双下跌

MedTrend医趋势2025-11-11

路透社消息：11月8日，辉瑞以最高100亿美元的价格击败诺和诺德，成功拿下减肥药新星Metsera。这场持续近两个月的收购战，落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会（FTC）的监管压力。此前，11月5日，FTC向诺和诺德发出警告信，指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》，并可能降低Metsera继续开发药物的动力。Metsera随后表示，诺和诺德的方案...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582908350?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-11 17:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582908350","market":"us","top_or_hot":-1,"title":"FTC出手，诺和诺德出局：辉瑞100亿美元收购Metsera后股价双双下跌","media":"MedTrend医趋势","content":"<div>\n<p>路透社消息：11月8日，辉瑞以最高100亿美元的价格击败诺和诺德，成功拿下减肥药新星Metsera。这场持续近两个月的收购战，落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会（FTC）的监管压力。此前，11月5日，FTC向诺和诺德发出警告信，指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》，并可能降低Metsera继续开发药物的动力。Metsera随后表示，诺和诺德的方案...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111183002a6f1c972&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FTC出手，诺和诺德出局：辉瑞100亿美元收购Metsera后股价双双下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFTC出手，诺和诺德出局：辉瑞100亿美元收购Metsera后股价双双下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-11 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111183002a6f1c972&s=b><strong>MedTrend医趋势</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>路透社消息：11月8日，辉瑞以最高100亿美元的价格击败诺和诺德，成功拿下减肥药新星Metsera。这场持续近两个月的收购战，落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会（FTC）的监管压力。此前，11月5日，FTC向诺和诺德发出警告信，指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》，并可能降低Metsera继续开发药物的动力。Metsera随后表示，诺和诺德的方案...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111183002a6f1c972&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111183002a6f1c972&s=b","article_id":"2582908350","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111183002a6f1c972&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582908350","pubTimestamp":1762851892,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"路透社消息：11月8日，辉瑞以最高100亿美元的价格击败诺和诺德，成功拿下减肥药新星Metsera。此前，11月5日，FTC向诺和诺德发出警告信，指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》，并可能降低Metsera继续开发药物的动力。Metsera随后表示，诺和诺德的方案存在\"不可接受的高法律和监管风险\"。从9月22日宣布初步收购协议至今，辉瑞股价累计下跌约3.6%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","FTC":"First Trust Large Cap Growth Opp","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4592":"伊斯兰概念","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4568":"美国抗疫概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4550":"红杉资本持仓","BK4588":"碎股","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4139":"生物科技","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","NVO":"诺和诺德","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","PFE":"辉瑞","SG9999002232.USD":"Allianz Global High Payout USD","BK4599":"减肥药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","MTSR":"Metsera Inc.","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"FTC moves, Novo Nordisk out: Pfizer both falls after $10 billion Metsera acquisition","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"PFE":1.5,"MTSR":1.5,"FTC":1.5},"content_text":"路透社消息：11月8日，辉瑞以最高100亿美元的价格击败诺和诺德，成功拿下减肥药新星Metsera。这场持续近两个月的收购战，落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会（FTC）的监管压力。此前，11月5日，FTC向诺和诺德发出警告信，指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》，并可能降低Metsera继续开发药物的动力。Metsera随后表示，诺和诺德的方案存在\"不可接受的高法律和监管风险\"。相比之下，辉瑞已提前获得FTC批准，这让其在竞标中占据明显优势。不过有意思的是：11月10日，Metsera股价下跌15.2%，至70.58美元；辉瑞股价下跌1.4%，至24.09美元。这一方面反映出市场对百亿收购价的估值担忧，另一方面也说明投资者对Metsera药物的上市时间和商业化前景持谨慎态度。从9月22日宣布初步收购协议至今，辉瑞股价累计下跌约3.6%。从投资角度看，这笔交易对辉瑞既是机遇也是挑战。机遇在于，如果MET-097i能够顺利通过Phase 3临床并成功上市，辉瑞将在2029年前后拥有一款差异化的减肥药产品，月度给药和良好的耐受性可能帮其抢占10-15%的市场份额。按照2030年1000亿美元的市场规模计算，这意味着年销售额有望达到100-150亿美元，将显著改善辉瑞的增长前景。挑战则在于执行风险。MET-097i还需要经历Phase 3大规模临床试验的考验，目前14.1%的减重效果能否在更大样本量中得到验证，2.9%的低停药率能否保持，以及月度给药的便利性能否转化为实际的市场竞争优势，都还存在不确定性。此外，到2028-2029年上市时，礼来和诺和诺德的下一代GLP-1产品（包括口服制剂和更长效的注射剂）可能已经占据市场，Metsera届时面临的竞争压力会更大。所以，市场对这笔交易的态度相对保守。Metsera股价下跌，一方面是对其产品的担忧，一旦考虑到与或有价值权相关的里程碑付款无法到位的风险，实际价值可能会更低。还有是因为辉瑞修改后的报价“并非全部是现金预付”。不过，辉瑞这笔收购也给市场传递了一个清晰信号：制药巨头不会放弃对减肥药市场的争夺。除了辉瑞和诺和诺德的竞价战，罗氏、诺华、默沙东等大型药企也在积极布局减肥药管线。未来3-5年，这个市场将从\"双寡头\"格局逐步演变为\"多强竞争\"，价格压力和市场份额的稀释不可避免。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582908350","isCrawlerRequest":true}